Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 68Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Biphenotypic, Acute 14Myelodysplastic Syndromes 12Leukemia 8Myeloproliferative Disorders 7Lymphoma, Mantle-Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelomonocytic, Chronic 4Blast Crisis 4Sarcoma, Myeloid 3Leukemia, Monocytic, Acute 3Down Syndrome 3Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hodgkin Disease 2Hematologic Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Targeted Therapy 1

Interventions

fludarabine 4fludarabine phosphate 3asciminib 3venetoclax 2gilteritinib 2Whole-Body Irradiation 2Tacrolimus 2Idarubicin 2Cytarabine 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2ponatinib 1nilotinib 1enasidenib 1blinatumomab 1aldesleukin 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Methotrexate 1Mesna 1Melphalan 1Interleukin-2 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid × Cytarabine × 90 days × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡